Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Recruiting

Phase 2

Candida VaccineCandida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Sponsor:

University of Arkansas

Code:

NCT05952934

Conditions

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

0.5 mL Candin®/injection

Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by University of Arkansas on 2025-05-15.